产品
编 号：F750824
分子式：C61H121N2O10P
分子量：1073.59
分子式：C61H121N2O10P
分子量：1073.59
产品类型
规格
价格
是否有货
结构图
CAS No: 2274812-94-9
产品详情
生物活性：
Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity.
体内研究：
Phospholipid PL1 (10 μg mRNA/mouse; i.t.; 6 times every other day; for 60 d) improves the immunotherapy with an anti-CD137 Ab and antitumor activity with an anti-OX40 Ab in tumor models with better results obtained in the B16F10 melanoma model than the A20 lymphoma model.Animal Model:B16F10 melanoma mouse model and A20 lymphoma mouse model (C57BL/6 mice)
Dosage:Administration of PL1-CD137 + anti-CD137 Ab; PL1-CD137 (10 μg mRNA/mouse), and anti-CD137 Ab (16 μg/mouse)
Administration:Intratumoral injection; 6 times every other day; 60 days
Result:Dramatically decreased the tumor growth rate by 5-fold (18 days after inoculation), and increased the overall survival time in B16F10 melanoma model.Resulted in a 2-fold decrease in the tumor growth rate (18d after inoculation) in A20 lymphoma model, without significant extension in the overall survival time.
Animal Model:B16F10 melanoma mouse model and CT26 colon carcinoma mouse model (C57BL/6 mice)
Dosage:Administration of PL1-OX40 + anti-OX40 Ab; PL1-OX40 (10 μg mRNA/mouse), and anti-OX40 Ab (8 μg/mouse)
Administration:Intratumoral injection; 6 times every other day; 60 days
Result:Significantly decreased the tumor growth and prolonged survival in comparison to treatment with PBS and PL1-OX40 + anti-OX40 Ab in both tumor models.
Phospholipid PL1 is a phospholipid-derived nanoparticle, can deliver costimulatory receptor mRNA (CD137 or OX40) to T cells. Phospholipid PL1 could induce the activation of various immune cells, including T cells and dendritic cells (DCs) in order to boost antitumor immunity.
体内研究：
Phospholipid PL1 (10 μg mRNA/mouse; i.t.; 6 times every other day; for 60 d) improves the immunotherapy with an anti-CD137 Ab and antitumor activity with an anti-OX40 Ab in tumor models with better results obtained in the B16F10 melanoma model than the A20 lymphoma model.Animal Model:B16F10 melanoma mouse model and A20 lymphoma mouse model (C57BL/6 mice)
Dosage:Administration of PL1-CD137 + anti-CD137 Ab; PL1-CD137 (10 μg mRNA/mouse), and anti-CD137 Ab (16 μg/mouse)
Administration:Intratumoral injection; 6 times every other day; 60 days
Result:Dramatically decreased the tumor growth rate by 5-fold (18 days after inoculation), and increased the overall survival time in B16F10 melanoma model.Resulted in a 2-fold decrease in the tumor growth rate (18d after inoculation) in A20 lymphoma model, without significant extension in the overall survival time.
Animal Model:B16F10 melanoma mouse model and CT26 colon carcinoma mouse model (C57BL/6 mice)
Dosage:Administration of PL1-OX40 + anti-OX40 Ab; PL1-OX40 (10 μg mRNA/mouse), and anti-OX40 Ab (8 μg/mouse)
Administration:Intratumoral injection; 6 times every other day; 60 days
Result:Significantly decreased the tumor growth and prolonged survival in comparison to treatment with PBS and PL1-OX40 + anti-OX40 Ab in both tumor models.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备